Castle Biosciences, Inc. filings document the regulatory record for a Delaware molecular diagnostics company with common stock listed on the Nasdaq Global Market under CSTL. Recent Form 8-K filings report quarterly and annual operating results, preliminary performance updates, and Regulation FD slide presentations tied to management communications.
The company’s proxy materials cover annual meeting matters, executive compensation, director elections, stockholder voting procedures, and governance disclosures. Other material-event filings document amendments to bylaws, including provisions related to stockholder meetings, director nominations, and board governance, alongside standing disclosures on registered securities and exchange listing status.
CSTL filing: Notice of proposed sales of Common Stock by reporting person Derek Maetzold
The filing lists multiple dispositions of Common stock by Derek Maetzold under a Form 144 notice, describing sales executed on various dates and securities acquired by gift and compensation (RSUs, PSUs, options). Several transactions in late 2025 and early 2026 are itemized with share counts and proceeds.
Castle Biosciences Chief Financial Officer Frank Stokes sold 6,001 shares of common stock on March 5, 2026 in an open-market transaction at a weighted-average price of $27.98 per share. The sale was made under a prearranged Rule 10b5-1 trading plan adopted on November 13, 2025.
The transaction was executed in multiple trades at prices ranging from $27.51 to $28.41 per share, with the reported price reflecting the weighted average. After this planned sale, Stokes continues to directly own 60,085 shares of Castle Biosciences common stock.
Castle Biosciences director Cole G Bradley reported option exercises and stock sales. On March 5, 2026, Bradley exercised stock options for 4,748 shares and received an equal number of common shares. He then sold a total of 7,403 common shares in open-market transactions and held 19,309 shares directly afterward.
Castle Biosciences Chief Commercial Officer Juvenal Tobin W reported several equity compensation transactions in early March 2026. On March 3, he received a grant of 48,367 Restricted Stock Units (RSUs), each representing one share of common stock, which will vest in four equal annual installments beginning March 3, 2027.
On March 4, previously granted RSUs were exercised into common stock, and 10,399 shares and 3,716 shares of common stock were withheld to cover tax obligations in connection with vested performance or restricted stock units. After these transactions, his directly held common stock and RSU positions increased overall.
Castle Biosciences Chief Operating Officer Kristen M. Oelschlager reported several equity compensation transactions involving restricted stock units (RSUs) and common stock. On March 3, 2026, she received a grant of 48,367 RSUs, which vest in four equal annual installments beginning on March 3, 2027.
On March 4, 2026, she exercised or converted RSUs covering 13,811 and 11,960 RSUs at a price of $0.00 per unit, resulting in 25,771 shares of common stock acquired through derivative exercises. The filing also reports dispositions of 6,792 and 2,427 shares of common stock at $28.17 and $27.57 per share, respectively, to satisfy tax withholding obligations in connection with vested performance stock units.
Following these transactions, she holds common stock directly and also has an indirect holding of 97,251 shares of common stock through The Fritz Shorter Trust, of which she and her spouse are trustees and beneficiaries. Each RSU represents the right to receive one share of Castle Biosciences common stock.
Castle Biosciences president and CEO Derek J. Maetzold reported several equity compensation transactions in company stock. On March 3, 2026, he received a grant of 102,597 Restricted Stock Units (RSUs), which, according to a footnote, vest in four equal annual installments beginning on March 3, 2027.
On March 4, 2026, RSUs previously granted were converted into a total of 59,097 shares of common stock through derivative exercises. On March 3 and March 4, 2026, a combined 36,974 shares of common stock were disposed of at prices of $27.57 and $28.17 per share to satisfy tax withholding obligations.
The filing also lists indirect holdings of common stock in multiple trusts, including The Maetzold Descendants 2020 Trust and several Maetzold remainder and grantor retained annuity trusts, where Maetzold or his spouse serves as trustee and certain family members are beneficiaries.
Castle Biosciences Chief Financial Officer Frank Stokes reported a mix of stock awards, option exercises, sales, and tax-related share withholdings. On March 3, 2026, he was granted 48,367 Restricted Stock Units (RSUs), each representing one share of common stock, vesting in four equal annual installments beginning March 3, 2027.
That same day, he sold 5,300 and 1,700 shares of common stock at weighted-average prices of $27.32 and $27.81 in open-market transactions under a Rule 10b5‑1 trading plan. He also disposed of 3,611 shares at $27.57 to cover tax withholding on previously vested performance stock units.
On March 4, 2026, Stokes exercised derivative awards, converting 12,186 and 11,960 RSUs and 3,800 fully vested stock options into common stock, including 3,800 shares at an exercise price of $3.38. After these transactions, he directly owned 66,086 common shares, including 1,033 shares acquired under the employee stock purchase plan.
Morgan Stanley Smith Barney LLC filed a Form 144 reporting proposed sales of Common shares for Franklin M. Stokes.
The notice lists a sale of 7,000 Common shares on 03/03/2026 for $192,045.00 and a sale of 4,496 Common shares on 12/11/2025 for $168,375.20. The filing references Restricted Stock Units dated 12/09/2023.
CSTL submitted a Form 144 notice reporting a proposed sale of 4,748 common shares via a stock option exercise dated 03/05/2026.
Broker/dealer listed is Morgan Stanley Smith Barney LLC. The filing also lists previously issued restricted stock quantities of 830 (06/10/2022) and 1,825 (06/02/2023).
Morgan Stanley Smith Barney LLC Executive Financial Services filed a Form 144 reporting an intended sale of 7,000 common shares originally issued as Restricted Stock Units on 12/09/2023. The filing lists a prior sale of 4,496 common shares on 12/11/2025 for $168,375.20.
The filing identifies the securities as common stock of CSTL and provides broker details and a filing date of 03/03/2026 in the header. This is a routine notice of an affiliate sale under resale reporting rules.